Aspen plans to take over Merck active pharmaceutical ingredient manufacturing plant
South Africa-based Aspen Pharmacare is considering buying active pharmaceutical ingredients (API) manufacturing plant in Netherlands from Merck's MSD unit.
In case reaching a final agreement, API operations are expected to remain in Oss while staff supporting the operations transfer with the business.
No specific details are finalized. The specifics will be subject to discussion and alignment with the Oss Works Council and Trade Union, according to MSD.
Aspen is owned in part by GlaxoSmithKline.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs